Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cardiff Oncology, Inc. (CRDF)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.28000.0000 (0.00%)
At close: 04:00PM EDT
1.3600 +0.08 (+6.25%)
After hours: 04:33PM EDT
Advertisement

Cardiff Oncology, Inc.

11055 Flintkote Avenue
San Diego, CA 92121
United States
858 952 7570
https://www.cardiffoncology.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees22

Key Executives

NameTitlePayExercisedYear Born
Dr. Mark Erlander Ph.D.CEO & Director783.23kN/A1960
Mr. James E. LevineChief Financial Officer585.16kN/A1971
Ms. Vicki KelemenChief Operating Officer512.24kN/AN/A
Dr. Tod Smeal Ph.D.Chief Scientific Officer?N/AN/AN/A
Ms. Elizabeth AndersonVP of Fin. & Admin.N/AN/AN/A
Mr. Charles Monahan R.Ph.Sr. VP of Regulatory AffairsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Corporate Governance

Cardiff Oncology, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 4. The pillar scores are Audit: 6; Board: 3; Shareholder Rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement